Aquestive Therapeutics
AQST· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +81.5% in FY2025
Daniel Barber is the CEO of Aquestive Therapeutics and was paid $3.5M in FY2025 (Dec), down 16%.
Pay$100 in the stock at the end of FY21 → $166
Executives3
See all- 1Daniel BarberPresident and Chief Executive OfficerFY2025
- 2Lori J. BraenderCorporate Secretary, Former Chief Legal Officer and Chief Compliance OfficerFY2025
- 3A. Ernest Toth, Jr.Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAquestive Therapeutics paid its 3 named executives $6.2M in total in FY2025 (Dec). CEO Daniel Barber was paid $3.5M of that.
| Name | |||
|---|---|---|---|
| Daniel BarberPresident and Chief Executive Officer | |||
| Lori J. BraenderCorporate Secretary, Former Chief Legal Officer and Chief Compliance Officer | |||
| A. Ernest Toth, Jr.Chief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Aquestive Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board2
See all- Julie Krop, M.D.Director · 4 yr on the boardIndependentCompensation, Nominating and Corporate Governance, Science and Technology (Chair)—Paid as an executive
- Timothy E. MorrisDirector · 3 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Mar 4, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 5, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 5, 2024 | FY2023 |
